Plasma fatty acid composition in French-Canadian children with non-alcoholic fatty liver disease: Effect of n-3 PUFA supplementation

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 99, Issue , 2015, Pages 25-34

  Spahis, S ^a,b,c   Alvarez, F ^a,b   Dubois, J ^a,b   Ahmed, N ^d   Peretti, N ^e   Levy, E ^a,b,c  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d MONTREAL CHILDREN S HOSPITAL   (Canada)

^e EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Fatty acids; N 3 fatty acids; NAFLD; Obesity; PUFA; Supplementation

Indexed keywords

ACYL COENZYME A DESATURASE 1; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LINOLEOYL COENZYME A DESATURASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOUNSATURATED FATTY ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; SATURATED FATTY ACID; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ANTHROPOMETRY; ARTICLE; CHILD; CITIZEN GROUP; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FATTY ACID ANALYSIS; FATTY ACID BLOOD LEVEL; FEMALE; FRENCH CANADIAN; HUMAN; LIPID COMPOSITION; MALE; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; BLOOD; DIETARY SUPPLEMENT; METABOLISM; QUEBEC;

ADOLESCENT; CHILD; DIETARY SUPPLEMENTS; FATTY ACIDS; FATTY ACIDS, OMEGA-3; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; QUEBEC;

EID: 84937522353     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2015.04.010     Document Type: Article

References (78)

1. Smith B.W., Adams L.A. Non-alcoholic fatty liver disease. Crit. Rev. Clin. Lab. Sci. 2011, 48:97-113.
2. Hui E., Xu A., Bo Y.H., Lam K.S. Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: role of adipokines. J. Diabetes Investig. 2013, 4:413-425.
3. Vanni E., Bugianesi E., Kotronen A., De M.S., Yki-Jarvinen H., Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa?. Dig. Liver Dis. 2010, 42:320-330.
4. Schwimmer J.B., Deutsch R., Kahen T., Lavine J.E., Stanley C., Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006, 118:1388-1393.
5. Berardis S., Sokal E. Pediatric non-alcoholic fatty liver disease: an increasing public health issue. Eur. J. Pediatr. 2014, 173:131-139.
6. Browning J.D., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
7. Parekh S., Anania F.A. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007, 132:2191-2207.
8. Marra F., Gastaldelli A., Svegliati B.G., Tell G., Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol. Med. 2008, 14:72-81.
9. Bieghs V., Trautwein C. The innate immune response during liver inflammation and metabolic disease. Trends Immunol. 2013, 34:446-452.
10. Lin Y.C., Chang P.F., Chang M.H., Ni Y.H. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. Am. J. Clin. Nutr. 2014, 99:869-874.
11. Karaman H., et al. Investigation of genome instability in patients with non-alcoholic steatohepatitis. World J. Gastroenterol. 2013, 19:5295-5301.
12. Del C.F., et al. Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications. Int. J. Mol. Sci. 2014, 15:684-711.
13. Kelishadi R., Poursafa P. Obesity and air pollution: global risk factors for pediatric non-alcoholic fatty liver disease. Hepat. Mon. 2011, 11:794-802.
14. Alisi A., Cianfarani S., Manco M., Agostoni C., Nobili V. Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. Ann. Med. 2012, 44:29-40.
15. Hamabe A., et al. Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. J. Gastroenterol. 2011, 46:769-778.
16. Nobili V. Non-alcoholic fatty liver disease in children and adolescents. Clin. Biochem. 2014.
17. Nanda K. Non-alcoholic steatohepatitis in children. Pediatr. Transplant 2004, 8:613-618.
18. Lavine J.E., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011, 305:1659-1668.
19. Bell L.N., et al. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology 2012, 56:1311-1318.
20. Malaguarnera M., et al. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis-a randomized and controlled clinical trial. Am. J. Gastroenterol. 2010, 105:1338-1345.
21. McCarthy E.M., Rinella M.E. The role of diet and nutrient composition in nonalcoholic Fatty liver disease. J. Acad. Nutr. Diet 2012, 112:401-409.
22. Koletzko B., et al. Dietary intake of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in children - a workshop report. Br. J. Nutr. 2010, 103:923-928.
23. Kris-Etherton P.M., Grieger J.A., Etherton T.D. Dietary reference intakes for DHA and EPA. Prostaglandins Leukot Essent Fatty Acids 2009, 81:99-104.
24. St-Jules D.E., et al. Estimation of fish and omega-3 fatty acid intake in pediatric nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr. 2013, 57:627-633.
25. Vajro P., Paolella G., Poeta M., Pizza C., Sangermano M., Massa G. Pediatric non alcoholic fatty liver disease: more on novel treatment targets. BMC Pediatr. 2013, 13:109.
26. Vajro P., et al. Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions. Ital. J. Pediatr. 2012, 38:55.
27. Wang C., et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am. J. Clin. Nutr. 2006, 84:5-17.
28. Lee J.H., O'Keefe J.H., Lavie C.J., Marchioli R., Harris W.S. Omega-3 fatty acids for cardioprotection. Mayo Clin. Proc. 2008, 83:324-332.
29. Ma Y., et al. A mutation in the human lipoprotein lipase gene as the most common cause of familial chylomicronemia in French Canadians. N. Engl. J. Med. 1991, 324:1761-1766.
30. Leitersdorf E., Tobin E.J., Davignon J., Hobbs H.H. Common low-density lipoprotein receptor mutations in the French Canadian population. J. Clin. Investig. 1990, 85:1014-1023.
31. De B.M., et al. Founder effect in familial hyperchylomicronemia among French Canadians of Quebec. Hum. Hered. 1991, 41:168-173.
32. Surette M.E. The science behind dietary omega-3 fatty acids. CMAJ 2008, 178:177-180.
33. Belanger S.A., et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatr. Child. Health 2009, 14:89-98.
34. Chahal N., Manlhiot C., Wong H., McCrindle B.W. Effectiveness of omega-3 polysaturated fatty acids (fish oil) supplementation for treating hypertriglyceridemia in children and adolescents. Clin. Pediatr. (Phila) 2014, 53:645-651.
35. Amminger G.P., et al. Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial. Can. J. Psychiatry 2013, 58:402-408.
36. Kromann N., Green A. Epidemiological studies in the Upernavik district, Greenland incidence of some chronic diseases 1950-1974. Acta Med. Scand. 1980, 208:401-406.
37. Spahis S., Vanasse M., Belanger S.A., Ghadirian P., Grenier E., Levy E. Lipid profile, fatty acid composition and pro- and anti-oxidant status in pediatric patients with attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 2008, 79:47-53.
38. Nobili V., et al. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr. Metab. Cardiovasc. Dis. 2013, 23:1066-1070.
39. Janczyk W., et al. Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial. BMC Pediatr. 2013, 13:85.
40. Scorletti E., et al. Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease. Contemp. Clin. Trials 2014, 37:301-311.
41. Nobili V., et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch. Dis. Child. 2011, 96:350-353.
42. Sofi F., et al. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. Int. J. Food Sci. Nutr. 2010, 61:792-802.
43. Ong J.P., Younossi Z.M. Epidemiology and natural history of NAFLD and NASH. Clin. Liver Dis. 2007, 11:1-16. vii.
44. Bril F., et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology 2014, 59:2178-2187.
45. Byrne C.D., Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb. Vasc. Biol. 2014, 34:1155-1161.
46. Lou D.J., et al. Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease. J. Diabetes Complicat. 2014.
47. Betard C., Kessling A.M., Roy M., Chamberland A., Lussier-Cacan S., Davignon J. Molecular genetic evidence for a founder effect in familial hypercholesterolemia among French Canadians. Hum. Genet. 1992, 88:529-536.
48. De B.M. Hereditary disorders in Saguenay-Lac-St-Jean (Quebec, Canada). Hum. Hered. 1991, 41:141-146.
49. Hamet P., et al. Quantitative founder-effect analysis of French Canadian families identifies specific loci contributing to metabolic phenotypes of hypertension. Am. J. Hum. Genet. 2005, 76:815-832.
50. Hobbs H.H., Brown M.S., Russell D.W., Davignon J., Goldstein J.L. Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. N. Engl. J. Med. 1987, 317:734-737.
51. Puri P., et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009, 50:1827-1838.
52. Lee J.J., et al. Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis. Am. J. Clin. Nutr. 2015, 101:34-43.
53. Rudkowska I., et al. Cardiometabolic risk factors are influenced by Stearoyl-CoA Desaturase (SCD) -1 gene polymorphisms and n-3 polyunsaturated fatty acid supplementation. Mol. Nutr. Food Res. 2014, 58:1079-1086.
54. Rossmeisl M., et al. Omega-3 phospholipids from fish suppress hepatic steatosis by integrated inhibition of biosynthetic pathways in dietary obese mice. Biochim. Biophys. Acta 2014, 1841:267-278.
55. Depner C.M., Philbrick K.A., Jump D.B. Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced nonalcoholic steatohepatitis. J. Nutr. 2013, 143:315-323.
56. Capanni M., et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol. Ther. 2006, 23:1143-1151.
57. Tanaka N., Sano K., Horiuchi A., Tanaka E., Kiyosawa K., Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2008, 42:413-418.
58. Allard J.P., et al. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J. Hepatol. 2008, 48:300-307.
59. Monteiro J., Leslie M., Moghadasian M.H., Arendt B.M., Allard J.P., Ma D.W. The role of n - 6 and n - 3 polyunsaturated fatty acids in the manifestation of the metabolic syndrome in cardiovascular disease and non-alcoholic fatty liver disease. Food Funct. 2014, 5:426-435.
60. Perreault M., et al. Plasma levels of 14:0, 16:0, 16:1n-7, and 20:3n-6 are positively associated, but 18:0 and 18:2n-6 are inversely associated with markers of inflammation in young healthy adults. Lipids 2014, 49:255-263.
61. Lepage G., Levy E., Ronco N., Smith L., Galeano N., Roy C.C. Direct transesterification of plasma fatty acids for the diagnosis of essential fatty acid deficiency in cystic fibrosis. J. Lipid Res. 1989, 30:1483-1490.
62. Mayneris-Perxachs J., et al. Plasma fatty acid composition, estimated desaturase activities, and their relation with the metabolic syndrome in a population at high risk of cardiovascular disease. Clin. Nutr. 2014, 33:90-97.
63. Steffen L.M., et al. Serum phospholipid and cholesteryl ester fatty acids and estimated desaturase activities are related to overweight and cardiovascular risk factors in adolescents. Int. J. Obes. (Lond) 2008, 32:1297-1304.
64. Yamamoto A., Yamamura T., Kawaguchi A., Kameda K., Matsuzawa Y. Triglyceride and glucose intolerance as a risk factor for coronary heart disease. Cardiology 1991, 78:185-193.
65. Mayer K., et al. Short-time infusion of fish oil-based lipid emulsions, approved for parenteral nutrition, reduces monocyte proinflammatory cytokine generation and adhesive interaction with endothelium in humans. J. Immunol. 2003, 171:4837-4843.
66. Tavazzi L., et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223-1230.
67. Sethom M.M., et al. Plasma fatty acids profile and estimated elongase and desaturases activities in Tunisian patients with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids 2011, 85:137-141.
68. Kawashima A., et al. Plasma fatty acid composition, estimated desaturase activities, and intakes of energy and nutrient in Japanese men with abdominal obesity or metabolic syndrome. J. Nutr. Sci. Vitaminol. (Tokyo) 2009, 55:400-406.
69. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 2005, 115:1343-1351.
70. Diraison F., Moulin P., Beylot M. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab. 2003, 29:478-485.
71. Gutierrez-Juarez R., et al. Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance. J. Clin. Invest. 2006, 116:1686-1695.
72. Dobrzyn A., Ntambi J.M. The role of stearoyl-CoA desaturase in body weight regulation. Trends Cardiovasc. Med. 2004, 14:77-81.
73. Li Z.Z., Berk M., McIntyre T.M., Feldstein A.E. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J. Biol. Chem. 2009, 284:5637-5644.
74. Araya J., Rodrigo R., Pettinelli P., Araya A.V., Poniachik J., Videla L.A. Decreased liver fatty acid delta-6 and delta-5 desaturase activity in obese patients. Obesity (Silver Spring) 2010, 18:1460-1463.
75. Zhu F.S., Liu S., Chen X.M., Huang Z.G., Zhang D.W. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J. Gastroenterol. 2008, 14:6395-6400.
76. Spadaro L., et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig. Liver Dis. 2008, 40:194-199.
77. Socha P., Horvath A., Vajro P., Dziechciarz P., Dhawan A., Szajewska H. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J. Pediatr. Gastroenterol. Nutr. 2009, 48:587-596.
78. Sanyal A.J., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010, 362:1675-1685.